China Nuokang Bio-Pharmaceutical Inc. to Reconvene Adjourned Extraordinary General Meeting of Shareholders
January 29 2013 - 8:00AM
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or
the "Company") announced today that it will reconvene the
extraordinary general meeting of shareholders (the "EGM") that was
previously adjourned on January 15, 2013. The EGM will be
reconvened at 9:30 a.m. (Beijing time) on February 6, 2013, at 26th
Floor, Gloucester Tower, The Landmark, 15 Queen's Road Central,
Hong Kong, to consider and vote on, among other things, the
proposal to authorize and approve the previously announced
agreement and plan of merger (the "Merger Agreement") dated
September 27, 2012, among the Company, Kingbird Investment Inc.
("Parent") and Kingbird Mergerco. Inc. ("Merger Sub"), and, solely
for the purposes of Section 6.16 thereof, Anglo China
Bio-technology Investment Holdings Limited and Britain Ukan
Technology Investment Holdings (Group) Limited, and the plan of
merger required to be filed with the Registrar of Companies of the
Cayman Islands, substantially in the form attached as Exhibit A to
the Merger Agreement (the "Plan of Merger") and the transactions
contemplated thereby (including the proposed merger).
About China Nuokang Bio-Pharmaceutical Inc.
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading
biopharmaceutical company in China focused on the research,
development, manufacture, marketing and sales of hospital-based
medical products. The Company provides a diversified portfolio of
products across more than 4,200 hospitals in China Nuokang's
principal products include Baquting®, China's leading hemocoagulase
product by market share, Kaitong®, a lipid emulsion alprostadil
product for the treatment of peripheral vascular diseases,
cardiocerebral microcirculation disorders and post-surgery
thrombosis; and alpha lipoic acid capsules, or ALA, an antioxidant
product that addresses diabetic neuropathy. The Company's product
pipeline includes product candidates under development in
hematological, cardiovascular and cerebrovascular disease
diagnosis, treatment and prevention. Please visit www.nkbp.com for
more information.
Forward-Looking Statements
This press release contains forward-looking statements relating
to the potential acquisition of the Company by an affiliate of Mr.
Baizhong Xue, the Chairman and Chief Executive Officer of the
Company. These are "forward-looking" statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, and
as defined in the U.S. Private Securities Litigation Reform Act of
1995. The actual results of the transaction could vary materially
as a result of a number of factors, including: uncertainties as to
how the Company's shareholders will vote at the extraordinary
general meeting; the possibility that competing offers will be
made; and the possibility that various closing conditions for the
transaction may not be satisfied or waived. These forward-looking
statements reflect the Company's expectations as of the date of
this press release. The Company does not undertake any obligation
to update any forward-looking statement, except as required under
applicable law.
CONTACT: China Nuokang Bio-Pharmaceutical Inc.
Mr. Steven Duan
Vice President of Investor Relations
Email: dsz@nkbp.com
ICR, Inc.
Mr. Rob Koepp
Tel: (+86) 10-6583-7516 or (646) 405-5180
Email: robert.koepp@icrinc.com
China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) (NASDAQ:NKBP)
Historical Stock Chart
From May 2024 to Jun 2024
China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) (NASDAQ:NKBP)
Historical Stock Chart
From Jun 2023 to Jun 2024